Latest Going Concern News

Papyrus Australia Limited reported a reduced half-year loss and marked a significant commercial milestone with a $4.2 million supply contract, advancing its transition from technology development to early-stage commercialisation.

SIV Capital Limited reported a 29.7% increase in its half-year loss to $172,763, with revenue down 41%, while its ASX suspension continues as it pursues a confidential transaction to regain listing status.

TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.

333D Limited reported a 23% increase in revenue to $588,678 for the half-year ended December 2025, despite a 92% plunge in profit after tax to a $282,030 loss. The company boosted its cash reserves significantly and initiated a strategic Bitcoin investment.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

PlaySide Studios reported a sharp 28% revenue decline for H1 FY26 but posted a remarkable 249% jump in profit, buoyed by cost cuts and a $7.8 million tax rebate. The company also secured a $6 million loan and inked a new global publishing deal.

Coronado Global Resources reported a $432.1 million net loss for FY2025, impacted by a 22% revenue decline due to softer metallurgical coal markets and logistical challenges. Despite operational gains and cost cuts, the company strengthened liquidity through refinancing and support from Stanwell.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Recharge Metals Limited has launched a pro-rata entitlement issue to raise $2.06 million, alongside a $3.97 million placement and a strategic acquisition of the Sunset Well Project in Western Australia. The capital raising aims to fund exploration and working capital, but shareholders face significant dilution and funding risks.

EMVision Medical Devices reported a $3.97 million loss for H1 2026, up 11% year-on-year, driven by increased share-based payments and expanded clinical activities. The company secured a $3 million government grant to advance stroke diagnosis in regional Australia.

Aurora Labs reported a 15% revenue decline and a 12% increase in net loss for H1 2026, yet marked a strategic breakthrough with its first defence propulsion order and a successful $5.5 million capital raise.

Multistack International Limited posted a surprising $2.26 million net profit for 2025, driven by one-off settlement income, while its core operations continue to falter, prompting plans to exit its current business model.